LLY
Wall Street’s still in Lilly’s corner
Truist Securities just waved the green flag again on Eli Lilly, repeating its Buy rating and a chunky $1,281 price target. Translation: despite all the noise around the company’s pipeline, Truist thinks the stock still has room to run.
The catalyst: positive Phase 3 data
The spark here was Foundayo’s Phase 3 trial results in type 2 diabetes. Positive late-stage data tends to make analysts perk up like they just heard the office lunch order includes tacos — because this is the kind of stuff that can turn a promising drug into a real business engine.
Why investors should care
Lilly has become one of the market’s favorite “show me more” names. When a big-name analyst firm reiterates a Buy after clinical progress, it can help keep sentiment sticky — especially for a company already carrying a massive valuation and a lot of expectations.
That said, this isn’t a free pass. Lilly’s pipeline has been dealing with regulatory pushback around its obesity/diabetes franchise, so investors are basically watching a very expensive juggling act: clinical wins in one hand, FDA headaches in the other.
Big picture
For now, Truist is saying the good news still outweighs the drama. If Lilly keeps stacking trial wins, the market may be willing to keep paying up — because in biotech-land, data is the ultimate plot twist.